SCIENTIFIC REPORTS

Received: 8 March 2017 Accepted: 26 June 2017 Published online: 04 September 2017

OPEN Tumor-infiltrating CD45RO⁺ **Memory T Lymphocytes Predict Favorable Clinical Outcome in Solid** Tumors

Guoming Hu¹ & Shimin Wang²

The prognostic role of tumor-infiltrating CD45RO⁺ memory T lymphocytes (CD45RO⁺ T cells) in human solid tumors remains controversial. Herein, we conducted a meta-analysis including 25 published studies with 4720 patients identified from PubMed and EBSCO to assess the prognostic impact of tumor-infiltrating CD45RO⁺T cells in human solid tumors. We found that CD45RO⁺T cell infiltration was significantly associated with improved overall survival (OS) and disease-free survival (DFS) in all types of solid tumors. In stratified analyses, CD45RO⁺T cell infiltration significantly improved 1-year, 3-year and 5-year OS in colorectal, gastric and esophageal cancer, but only 5-year OS in hepatocellular carcinoma. And these cells were positively associated with 1-year, 3-year and 5-year DFS in hepatocellular, colorectal and esophageal cancer. In addition, high density of intratumoral CD45RO⁺T cells inversely correlated with TNM stage of solid tumor. In conclusion, CD45RO⁺ memory T lymphocyte infiltration leads to a favorable clinical outcome in solid tumors, implicating that it is a valuable biomarker for prognostic prediction for human solid malignances.

Accumulating evidence has demonstrated that tumor microenvironment (TME) linked closely with the initiation, promotion, and progression of cancer¹. Tumor-infiltrating lymphocytes (TILs) are the major component of TME². Previous studies have revealed that TILs were significantly positively associated with survival of solid tumors³. However, it is important to distinguish among different types of T lymphocytes as they may play differential roles in the TME. CD45RO⁺ memory T lymphocytes (CD45RO⁺ T cells), as the important component of TILs, have been demonstrated to play specific and significant roles in a number of human cancers.

CD45 is known as the leukocyte common antigen, and functions as a tyrosine phosphatase in leukocyte signaling. The expression of different CD45 isoforms is cell - type specific and depends on the state of activation and the stage of differentiation of cells. CD45RO is the most suitable single marker for human memory T cells, that can finely represent the activation status of T cells⁴. CD45RO⁺ T cells often increased in solid tumors. Recent studies have associated CD45RO⁺ T cells and cancer prognosis, but their results were controversial. Thus, an in-depth assessment is warranted. Moreover, the potential of these cells as an effective biomarker in prognostic prediction is necessary to be explored.

Here, we performed this meta-analysis to test overall survival (OS) and disease-free survival (DFS) as outcomes in patients with solid tumor with known intratumoral CD45RO⁺ T cell density evaluated by immunohistochemistry (IHC). The aim of this study was to quantitatively summarize the association between CD45RO⁺ T cell infiltration and clinical outcomes in cancer patients, and thereby provided more evidence on the clinical value of tumor-infiltrating CD45RO⁺T cells as a prognostic biomarker for solid malignances.

Materials and Methods

Search strategy. We searched PubMed and EBSCO for studies assessing the density of CD45RO⁺ T cells in tumor tissue and survival in patients with solid tumor from 1996 to January 15th 2017. The searching keywords were (CD45RO [Title/Abstract]) AND (neoplasms [Title/Abstract] OR cancer [Title/Abstract] OR tumor [Title/

¹Department of General Surgery (Breast and Thyroid Surgery), Shaoxing People's Hospital; Shaoxing Hospital of Zhejiang University, 312000, Zhejiang, China. ²Department of Nephrology, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, 312000, Zhejiang, China. Correspondence and requests for materials should be addressed to G.H. (email: hgmplj@126.com)



Figure 1. Flow chart diagram of study selection.

.....

Abstract] OR carcinoma [Title/Abstract]). A total of 724 and 1847 entries were identified in PubMed and EBSCO respectively.

Inclusion and exclusion criteria. Inclusion criteria of the meta-analysis were: studies included must have (1) been published as original articles; (2) evaluated human subjects; (3) CD45RO⁺ T cells in tumor specimens were evaluated by IHC; (4) provided Kaplan – Meier curves of high and low CD45RO⁺ T cell density with overall survival (OS), and/or disease-free survival (DFS), or relapse-free survival (RFS); (5) published in English.

We excluded studies that were not published as full texts, including commentary, case report, conference abstracts and letters to editors, studies that not report sufficient data to estimate survival rates; studies that evaluated CD45RO⁺ T cells with Flow Cytometry (FCM) or real-time reverse transcription polymerase chain reaction (RT-PCR), detected CD45RO⁺ T cells in metastases and not in tumor tissues.

Endpoints. OS and DFS (or RFS) were the endpoints used in this meta-analysis. OS was recorded as the primary endpoint, and the second endpoint was DFS (or RFS). Cut-offs of CD45RO⁺ T cell density defined by individual studies classified cancer patients into high- and low- groups.

Data extraction. Two authors (G.M.H. and S.M.W.) independently reviewed and extracted data using predefined data abstraction form from each eligible study. Extracted information included first author's name, publication year, country, number of patients, median age, gender, Tumor, Lymph Node, Metastasis (TNM) stage, tumor differentiation, time of follow-up, technique used to quantify CD45RO⁺ T cells, and cut-off value to determine high CD45RO⁺ T cell density. OS, DFS (or RFS) and clinicopathological data were extracted from the text, tables, or Kaplan – Meier curves for both high and low CD45RO⁺ T cell density groups.

Quality assessment. The studies included in the meta-analysis were cohort studies. The quality of each included study was assessed using Newcastle–Ottawa Scale (NOS) by two independent authors⁵. The studies with 6 scores or more were classified as high quality studies. A consensus NOS score for each item was achieved.

Statistical Analysis. Extracted data were combined into a meta-analysis using STATA 12.0 analysis software (Stata Corporation, College Station, TX, USA). Statistical heterogeneity was assessed using the chi-squared based Q-test or the I^2 method⁶. Data were combined according to the random-effect model in the presence of heterogeneity⁷, otherwise, the fixed-effect model was performed⁸). Sensitivity analysis was employed to assess the influence of each study on the pooled result. Begg's funnel plot and Egger's test⁹ were calculated to investigate potential publication bias. All *P* values were two-sided and less than 0.05 are considered statistically significant.

Study	Year	Tumor type	No. of Patients	Male/ Female	median age (range) (year)	CD45RO ⁺ T: High/Low	Tumor stage	median follow-up date (months)	Survival	Quality Score (NOS)
Yajima, R. <i>et al</i> . ¹⁰	2016	Breast cancer	98	0/98	NR	49/49	I–III	84	OS, DFS	6
Zhang, Z. et al.11	2015	Ovarian cancer	33	0/33	50.33 ± 10.84	31/2	I–IV	35 (1, 126)	OS	6
Paulsen, E. E. et al. ¹²	2015	Non-small cell lung cancer	504	343/161	≤65: 45%; >65: 55%	423/81	I–III	61 (0.3, 81.6)	OS	7
Gao, Q. <i>et al</i> . ¹³	2012	Hepatocellular carcinoma	206	186/20	≤49: 50.5%; >49: 49.5%	103/103	I–III	48.1 (3.4, 111.9)	OS, DFS	8
Hotta, K. <i>et al</i> . ¹⁴	2011	Renal cell carcinoma	105	76/29	<60: 34.3%; ≥60: 65.7%	52/53	I–IV	15.9 (2, 52.5)	OS	7
Wakatsuki, K. <i>et al.</i> ¹⁵	2013	Gastric cancer	74	54/20	65 (36, 84)	37/37	I–IV	NR	OS, DFS	7
Lee, H. E. <i>et al</i> . ¹⁶	2008	Gastric cancer	220	156/64	<66: 80.5%; ≥66: 19.5%	65/155	I–IV	NR	OS	7
Li, Y. W. et al. ¹⁷	2009	Hepatocellular carcinoma	302	260/42	$\leq 60:76.8\%;>60:$ 23.2%	150/152	I–III	58 (2, 121)	OS, DFS	7
Enomoto, K. et al. ¹⁸	2012	Esophageal cancer	105	85/20	61-4 (42, 78)	54/51	I–IV	NR	OS, DFS	7
Chang, K. C. et al. ¹⁹	2007	Diffuse Large B-Cell Lymphomas	48	27/21	$\leq 60:39.6\%;>60:60.4\%$	18/30	I–IV	NR	OS	6
Anraku, M. et al. ²⁰	2008	Malignant pleural mesothelioma	32	28/4	59 (21, 74)	15/14	II–IV	35 (9, 63)	OS	6
Rauser, S. et al. ²¹	2010	Esophageal cancer	110	102/8	63.6 (33, 83)	93/17	I–IV	33 (0.8, 164)	OS, DFS	7
Brunner, S. et al. ²²	2014	Colorectal cancer	121	NR	62 (53, 68)	63/58	IV	NR	OS	6
de Jong, R. A. <i>et al</i> ²³	2009	Endometrial cancer	298	0/298	65 (32, 89)	181/117	I–IV	4.4 (0, 21.5)	OS	6
Zhang, Y. et al. ²⁴	2016	Gallbladder carcinoma	98	51/47	63 (39, 88)	48/50	I–IV	NR	OS	7
Lee, W. S. <i>et al</i> . ²⁵	2010	Colorectal cancer	53	29/34	$\leq 60:47.2\%;>60:$ 52.8%	25/28	II	NR	OS, DFS	7
Galon, J. et al. ²⁶	2006	Colorectal cancer	243	NR	NR	121/122	I–IV	45.3	OS, DFS	7
Peng, R. Q. <i>et al</i> . ²⁷	2010	Colorectal cancer	72	40/32	<60: 45.8%; ≥60: 54.2%	54/18	IIIB	NR	OS	6
Wang, L. et al. ²⁸	2015	Colorectal cancer	185	110/75	58 (22, 85)	91/94	I–III	NR	OS	7
Pages, F. et al. ²⁹	2005	Colorectal cancer	336	NR	NR	160/176	Dukes' A-D	44.5	OS, DFS	8
Koelzer, V. H. et al. ³⁰	2014	Colorectal cancer	130	80/50	NR	65/65	I–IV	NR	OS	7
Kim, Y. H. <i>et al</i> . ³¹	2015	Colorectal cancer	218	133/85	<65: 54.6%; ≥65: 45.4%	103/115	I–IV	NR	OS	7
Lee, W. S. et al ³²	2013	Colorectal cancer	94	NR	NR	46/48	IV	39.1 (3, 75)	OS	7
Nosho, K. et al. ³³	2010	Colorectal cancer	738	NR	NR	356/382	I–IV	11.6	OS	7
Chen, Y. F. et al. ³⁴	2016	Colorectal cancer	300	158/142	<60: 48%; ≥60: 52%	112/188	I–IV	62.9±29.3	OS, DFS	8

Table 1. Main characteristics of the included studies.

Result

Search results and description of studies. Literature searches yield 2571 records and the results were shown in Fig. 1. 25 studies containing 4720 patients with solid tumor were identified for the assessment of tumor-infiltrating CD45RO⁺ T cells^{10–34}. All the studies were evaluated by the Newcastle–Ottawa Scale (NOS), and were in accordance with the inclusion criteria and suitable for data consolidation. Characteristics of included studies for OS, DFS and clinicopathological features such as TNM stage, tumor differentiation *et al.* were shown in Table 1 and Table S1 respectively.

Meta-analyses. Overall survival (OS). The meta-analysis showed that $CD45RO^+$ T cells infiltrating into tumor was significantly associated with better 1-year (OR = 1.74, 95% CI 1.30 to 2.33, P = 0.000) and 3-year OS (OR = 2.17, 95% CI 1.65 to 2.86, P = 0.000) in patients with solid tumor (Fig. 2A and B); Similar results were observed between CD45RO⁺ T cells and 5-year (OR = 2.03, 95% CI 1.51 to 2.72, P = 0.000) and 10-year OS (OR = 1.85, 95% CI 1.44 to 2.38, P = 0.000) (Fig. 2C and D).

In stratified analyses by cancer types, as shown in Fig. 3, pooled results showed that high density of CD45RO⁺ T cells significantly improved OS at 1-year (OR = 1.77, 95% CI 1.15 to 2.72, P = 0.009), 3-year (OR = 2.79, 95% CI 1.80 to 4.30, P = 0.000) 5-year (OR = 2.48, 95% CI 1.67 to 3.69, P = 0.000) and 10-year (OR = 1.66, 95% CI 1.13 to 2.43, P = 0.010) in colorectal cancer (CRC) as well as 1-year (OR = 2.59, 95% CI 1.22 to 5.49, P = 0.013), 3-year (OR = 2.35, 95% CI 1.38 to 4.04, P = 0.002) and 5-year OS (OR = 2.19, 95% CI 1.31 to 3.67, P = 0.003) in gastric cancer (GC); Similar results were observed between CD45RO⁺ T cells and 1-year (OR = 3.97, 95% CI 1.89



Figure 2. Forest plots describing ORs of the association between CD45RO⁺ T cell infiltration and OS at 1-year, 3-year, 5-year and 10-year.

.....

to 8.34, P = 0.000), 3-year (OR = 3.08, 95% CI 1.62 to 5.86, P = 0.001) and 5-year OS (OR = 2.66, 95% CI 1.34 to 5.29, P = 0.005) of esophageal carcinoma (EC) patients. However, in hepatocellular carcinoma (HCC), we found CD45RO⁺ T cell infiltration was significantly associated with improved 5-year (OR = 1.54, 95% CI 1.08 to 2.20, P = 0.016), but not with 1-year (OR = 1.59, 95% CI 0.92 to 2.76, P = 0.095) or 3-year OS (OR = 1.44, 95% CI 1.00 to 2.08, P = 0.050). By the way, there was only one study reporting the relevant data for OS in breast, ovarian, cervical, endometrial cancer and non-small cell lung cancer (NSCLC), gallbladder, renal cell carcinoma, diffuse large B-cell lymphomas, malignant pleural mesothelioma respectively, thus, we couldn't get a combined result for them.

Study			Events,	Events,	%
A, 1 - Year OS		OR (95% CI)	CD45RO-High	CD45RO-Low	Weight
CRC					
Brunner,S. etal (2014)	-	0.65 (0.23, 1.81)	52/63	51/58	10.29
Wang,L. etal (2015)		3.13 (1.17, 8.34)	85/91	77/94	10.81
Pages, F. etal (2005)		2.58 (1.50, 4.41)	138/160	121/178	17.88
Koezer, V. H. etal (2014) Kim, Y. H. etal (2015)		1.88 (0.81, 4.38) 1.03 (0.38, 2.93)	54/00 98/103	47/05	9.97
Lee,W.S. etal (2013)	<u> </u>	3.11 (1.20, 8.10)	38/48	29/48	11.10
Nosho,K. etal (2010) -	•	0.99 (0.60, 1.61)	322/358	346/382	18.72
Lee,W. S. etal (2010)		(Excluded)	25/25	28/28	0.00
Subtotal (i-squared = 50.3%, p = 0.041)	\diamond	1.77 (1.15, 2.72)	971/1075	1000/1172	100.00
Gao,Q. etal (2012)		2.14 (0.97, 4.71)	92/103	82/103	47.38
Li,Y.W. etal (2009)	*	1.22 (0.58, 2.58)	138/150	135/152	52.64
	\sim	1.00 (0.02, 2.70)	220/200	211/200	100.00
Gastric cancer					
Wakatsuki,K. etal (2013) -	•	2.28 (0.62, 8.35)	33/37	29/37	33.47
Subtotal (I-squared = 0.0%, p = 0.811)	\sim	2.59 (1.22, 5.49)	92/102	150/192	100.00
<u>.</u>					
Esophageal carcinoma Enomoto,K. etal (2012)	•	3.41 (1.33, 8.75)	48/54	32/51	62.27
Rauser,S. etal (2010)		5.09 (1.52, 17.08)	84/93	11/17	37.73
Subtotal (I-squared = 0.0%, p = 0.608)	\sim	3.97 (1.89, 8.34)	130/147	43/68	100.00
B, 3 - Year OS					
CRC	_				
Brunner, S. etal (2014)	+• .	1.63 (0.79, 3.35)	39/63	29/58	10.87
Peng.R.Q. etal (2010)		9.80 (2.66, 36.10)	49/54	20/28 9/18	6.48
Wang,L. etal (2015)		3.75 (1.75, 8.04)	80/91	62/94	10.53
Pages, F. etal (2005)		2.58 (1.82, 4.02)	115/160	88/178	13.30
Koezer, V.H.etal (2014) Kim Y.H. etal (2015)		4.05 (1.92, 8.55)	49/65 79/103	28/65	10.65
Lee,W.S. etal (2013)		10.45 (3.94, 27.7	5) 38/48	15/48	8.71
Nosho,K. etal (2010)	÷	1.22 (0.88, 1.73)	284/358	292/382	14.13
Chen, Y.F. etal (2016)	*	2.47 (1.29, 4.72)	98/112	139/188	11.58
	\sim	2.18 (1.80, 4.80)	850/10/5	100/11/2	100.00
нсс					
Gao.Q. etal (2012)		1.74 (0.98, 3.11)	73/103	60/103 93/152	39.89 60.11
Subtotal (I-squared = 0.0%, p = 0.403)	\diamond	1.44 (1.00, 2.08)	173/253	153/255	100.00
1	-				
Wakatsuki.K. etal (2013)		2.49 (0.96, 6,49)	28/37	18/37	32.31
Lee,H.E. etal (2008)		2.28 (1.18, 4.42)	50/65	92/155	67.69
Subtotal (I-squared = 0.0%, p = 0.881)	\diamond	2.35 (1.38, 4.04)	76/102	110/192	100.00
Esophageal carcinoma					
Enomoto.K. etal (2012)		3.18 (1.43, 7.10)	32/54	16/51	64.35
Rauser, S. etal (2010) Subtotal (I-souared = 0.0%, p = 0.894)	\sim	2.90 (0.99, 8.54) 3.08 (1.82, 5.88)	57/93 89/147	6/17 22/68	35.65
	\sim				
0.5					
C, 5 - Year US	1				
Lee.W. S. etal (2010)		9.37 (0.48, 183.30	0 25/25	24/28	1.62
Galon, J. Etal (2008)		1.89 (1.11, 3.21)	88/121	69/122	13.71
Peng,R.Q. etal (2010)		14.95 (4.17, 53.54	6) 48/54	5/18	6.32
Pages, F. etal (2005) Koelzer V. H. etal (2014)		3.00 (1.92, 4.67) 2.58 (1.28, 5.20)	41/85	64/1/6 28/85	14.81
Kim, Y.H. etal (2015)		1.40 (0.79, 2.48)	73/103	73/115	13.23
Lee,W.S. etal (2013)		5.91 (2.37, 14.75)	28/48	10/48	9.25
Nosho,K. etal (2010) Chen Y. F. etal (2016)	•	1.31 (0.95, 1.81)	262/356 91/112	253/372	18.25
Subtotal (I-squared = 71.3%, p = 0.001)	6	2.48 (1.67, 3.69)	753/1042	653/1132	100.00
1	-				
HUU Gao.Q. etal (2012)		1.92 (1.09: 3.39)	70/103	54/103	38.95
Li.Y.W. etal (2009)		1.34 (0.85, 2.10)	79/150	69/152	61.05
Subtotal (I-squared = 0.0%, p = 0.328)	\diamond	1.54 (1.08, 2.20)	149/253	123/255	100.00
Gastrio cancer					
Wakatsuki,K. etal (2013)	• • • • • • • • • • • • • • • • • • •	2.41 (0.95, 6.13)	22/37	14/37	30.64
Lee, H.E. etal (2008)	÷.	2.10 (1.13, 3.91)	48/85	83/155	69.38
Subtotal (I-squared = 0.0%, p = 0.810)	\sim	2.19 (1.31, 3.67)	68/102	97/192	100.00
Esophageal carcinoma					
Enomoto, K. etal (2012)		2.60 (1.12, 6.03)	24/54	12/51	68.80
reauser, 5. etal (2010) Subtotal (I-squared = 0.0%, p = 0.923)	i co	2.79 (0.85, 9.21) 2.68 (1.34, 5.29)	43/93 67/147	4/17 16/68	33.20 100.00
	-				
	1				
D, 10 - Year OS	1				
CBC					
UNU					
Lee,W. S. etal (2010) -	· · · · · · · · · · · · · · · · · · ·	6.55 (0.73, 58.7	6)24/25	22/28	2.87
	-			ee	er = :
Pages,F. etal (2005)		2.40 (1.53, 3.76	6) 78/160	50/176	29.74
Nosho,K. etal (2010)	•	1.44 (1.07, 1.93) 218/356	200/382	39.10
	L				
Chen,Y.F. etal (2016)	•	1.19 (0.74, 1.92	2) 69/112	108/188	28.29
Subtotal (Learnarad = 54 09' 0.004)		1 66 /1 12 2 **	n 380/FF2	380/774	100.00
Suurorai (I-squareo = 54.3%, p = 0.084)	ee	1.00 (1.13, 2.43	9 303/653	300///4	100.00
NOTE: Weights are from random effects analysis					
		1			
.01	1 1	00			

Figure 3. Stratified analyses describing ORs of the association between CD45RO⁺ T cell infiltration and OS at 1-year, 3-year, 5-year and 10-year.

.....

Disease-free survival (DFS). Meta-analysis showed that CD45RO⁺ T cell infiltration was significantly associated with improved 1-year (OR = 2.23, 95% CI 1.69 to 2.94, P = 0.000), 3-year (OR = 2.25, 95% CI 1.80 to 2.82, P = 0.000) and 5-year DFS (OR = 2.14, 95% CI 1.63 to 2.79, P = 0.000), but not with 10-year (OR = 1.70, 95% CI 0.92 to 3.15, P = 0.091) DFS in solid tumors (Fig. 4).

In stratified analyses by cancer types, as shown in Fig. 5, increased density of CD45RO⁺ T cells within tumor was significantly associated with better 1-year (OR = 3.14, 95% CI 2.00 to 4.93, P = 0.000), 3-year (OR = 2.56, 95% CI 1.79 to 3.65, P = 0.000) and 5-year DFS (OR = 1.99, 95% CI 1.31 to 3.03, P = 0.001), but not with 10-year DFS (OR = 2.04, 95% CI 0.86 to 4.84, P = 0.104) in colorectal cancer. CD45RO⁺ T cell infiltration also improved 1-year

Study			Events,	Events.	%
ID		OR (95% CI)	CD45RO-High	CD45RO-Low	Weight
A, 1 - Year DFS					
Yajima,R. etal (2018) —		1.00 (0.14, 7.40)	47/49	47/49	1.88
Gao.Q. etal (2012)	•	1.48 (0.80, 2.67)	77/103	69/103	18.78
Wakatsuki,K. etal (2013)		2.29 (0.87, 6.07)	27/37	20/37	7.74
Li,Y.W. etal (2009)	•	1.70 (0.98, 2.97)	124/150	112/152	21.87
Enomoto,K. etal (2012)	· · ·	1.97 (0.87, 4.45)	39/54	29/51	10.88
Rauser,S. etal (2010)		5.47 (1.79, 18.74)	80/93	9/17	5.90
Lee,W. S. etal (2010)		- 7.00 (0.34, 142.52)	25/25	25/28	0.83
Pages, F. etal (2005)		3.13 (1.89, 5.17)	131/160	104/178	28.15
Chen, Y.F. etal (2016)	•	2.88 (0.94, 8.67)	108/112	170/188	5.99
Overall (I-squared = 5.4%, p = 0.390)	\diamond	2.23 (1.69, 2.94)	658/783	585/801	100.00
P 2 Year DES					
D, J - Teal DFO					
Yajima,R. etal (2016)		2.99 (0.74, 12.04)	48/49	41/49	2.59
Gao,Q. etal (2012)		2.13 (1.22, 3.72)	66/103	47/103	18.04
Wakatsuki,K. etal (2013)		2.71 (1.08, 8.94)	22/37	13/37	5.65
Li,Y.W. etal (2009)	•	1.55 (0.98, 2.44)	92/150	77/152	23.98
Enomoto,K. etal (2012)		3.23 (1.44, 7.28)	31/54	15/51	7.66
Rauser,S. etal (2010)		2.43 (0.83, 7.13)	53/93	6/17	4.33
Lee.W. S. etal (2010)		 9.60 (1.11, 83.40) 	24/25	20/28	1.07
Pages.F. etal (2005)		2.68 (1.68, 4.20)	117/160	89/176	23.92
Chen, Y.F. etal (2018)		2.18 (1.22, 3.91)	93/112	130/188	14.77
Overall (I-squared = 0.0%, p = 0.847)	\diamond	2.25 (1.80, 2.82)	544/783	438/801	100.00
C, 5 - Year DFS	1				
Yajima,R. etal (2018)		3.93 (1.01, 15.30)	48/49	39/49	3.49
Gao.Q. etal (2012)		2.20 (1.28, 3.83)	62/103	42/103	13.85
Wakatsuki,K. etal (2013)		3.18 (1.20, 8.39)	20/37	10/37	6.23
Li,Y.W. etal (2009)		1.37 (0.87, 2.16)	78/150	67/152	17.37
Enomoto,K. etal (2012)		3.15 (1.38, 7.19)	28/54	13/51	8.07
Rauser,S. etal (2010)		- 6.18 (1.34, 28.55)	42/93	2/17	2.81
Lee,W. S. etal (2010)		- 5.45 (1.05, 28.32)	23/25	19/28	2.45
Galon, J. Etal (2006)		1.27 (0.72, 2.24)	91/121	85/122	13.55
Chee V.E. etal (2018)		2.01 (1.07, 4.10)	98/112	121/100	17.51
Overall (I-sourced = 31.6%, p = 0.158)		2 14 (1 83, 2 79)	588/904	482/923	100.00
D, 10 - Year DFS					
Li,Y.W. etal (2009)		1.14 (0.72, 1.81)	61/150	57/152	29.20
	100				
Lee,W. S. etal (2010)	•	- 3.47 (0.82, 14.71)	22/25	19/28	11.98
Pages.F. etal (2005)		3.03 (1.94, 4.75)	110/160	74/176	29.48
Chen,Y.F. etal (2018)	<u> </u>	1.08 (0.87, 1.87)	62/122	93/188	29.34
Overall (I-squared = 78.8%, p = 0.003)	$\langle \rangle$	1.70 (0.92, 3.15)	255/457	243/544	100.00
NOTE: Weights are from random effects analysis					
	5 1 2				

Figure 4. Forest plots describing ORs of the association between CD45RO⁺ T cell infiltration and DFS at 1-year, 3-year, 5-year and 10-year.

....

(OR = 1.59, 95% CI 1.05 to 2.39, P = 0.027), 3-year (OR = 1.76, 95% CI 1.23 to 2.50, P = 0.002) and 5-year DFS (OR = 1.69, 95% CI 1.07 to 2.66, P = 0.024) in HCC as well as 1-year (OR = 3.05, 95% CI 1.13 to 8.23, P = 0.028), 3-year (OR = 2.92, 95% CI 1.53 to 5.57, P = 0.001) and 5-year DFS (OR = 3.66, 95% CI 1.77 to 7.58, P = 0.000) in esophageal carcinoma.

We next investigated whether CD45RO⁺ T cell infiltration was associated with clinicopathological features such as TNM stage, tumor differentiation, Lymphatic invasion and vascular invasion of solid tumor. We found that CD45RO⁺ T cell infiltration was significantly inversely correlated with TNM stage (OR=1.59, 95% CI 1.03 to 2.45, P=0.038), but not with tumor differentiation (OR=1.25, 95% CI 0.83 to 1.90, P=0.285), lymphatic

Study Events Events 5 OR (95% CI) CD45RO-High CD45RO-Low Weight A, 1 - Year DFS CRC Lee,W. S. etal (2010) 2.25 7.00 (0.34, 142.52) 25/25 25/28 Pages, F. etal (2005) 3.13 (1.89, 5.17) 131/160 104/178 81.14 Chen, Y.F. etal (2016) 2.88 (0.94, 8.67) 108/112 170/188 16.60 Subtotal (I-squared = 0.0%, p = 0.881) \sim 3.14 (2.00, 4.93) 284/297 299/392 100.00 нсс Gao,Q. etal (2012) 1.48 (0.80, 2.67) 77/103 45.78 69/103 Li,Y.W. etal (2009) 1.70 (0.98, 2.97) 124/150 112/152 54.24 Subtotal (I-squared = 0.0%, p = 0.712) 100.00 1.59 (1.05, 2.39) 201/253 181/255 Esophageal carcin Enomoto,K. etal (2012) 1.97 (0.87, 4.45) 39/54 29/51 57.31 Rauser,S. etal (2010) 5.47 (1.79, 16.74) 80/93 42.69 9/17 Subtotal (I-squared = 52.5%, p = 0.147) 3.05 (1.13, 8.23) 110/147 38/68 100.00 B, 3 - Year DFS CRC Lee.W. S. etal (2010) 9.60 (1.11, 83.40) 24/25 20/28 2.70 Pages, F. etal (2005) 2.68 (1.68, 4.20) 117/160 89/178 60.16 Chen, Y.F. etal (2016) 2.18 (1.22, 3.91) 93/112 130/188 37.15 Subtotal (I-squared = 0.0%, p = 0.416) 2.58 (1.79, 3.65) 234/297 239/392 100.00 нсс Gao.Q. etal (2012) 2.13 (1.22. 3.72) 68/103 47/103 40.10 Li,Y.W. etal (2009) 1.55 (0.98, 2.44) 92/150 77/152 59.90 Subtotal (I-squared = 0.0%, p = 0.387) 1.76 (1.23, 2.50) 158/253 124/255 100.00 Esophageal carcinoma Enomoto.K. etal (2012) 3.23 (1.44, 7.26) 31/54 15/51 63.92 Rauser,S. etal (2010) 2.43 (0.83, 7.13) 53/93 6/17 38.08 Subtotal (I-squared = 0.0%, p = 0.877) 2.92 (1.53, 5.57) 84/147 21/68 100.00 C, 5 - Year DFS CRC Lee.W. S. etal (2010) 5.45 (1.05, 28.32) 23/25 19/28 5.80 Galon, J. Etal (2008) 1.27 (0.72, 2.24) 91/121 88/122 28.44 . Pages, F. etal (2005) 2.61 (1.67, 4.10) 112/160 83/178 35.33 . Chen,Y.F. etal (2016) 1.83 (1.08, 3.11) 88/112 121/188 30.43 Subtotal (I-squared = 44.0%, p = 0.147) 1.99 (1.31, 3.03) 312/418 309/514 100.00 нсс Gao,Q. etal (2012) 2.20 (1.28, 3.83) 62/103 42/103 43.78 Li,Y.W. etal (2009) 1.37 (0.87, 2.16) 78/150 67/152 58.22 Subtotal (I-squared = 39.0%, p = 0.201) 1.69 (1.07, 2.66) 140/253 109/255 100.00 Esophageal carcin Enomoto,K. etal (2012) 3.15 (1.38, 7.19) 28/54 13/51 77 47 Rauser.S. etal (2010) 6.18 (1.34, 28.55) 42/93 2/17 22.53 Subtotal (I-squared = 0.0%, p = 0.442) 3.66 (1.77, 7.58) 70/147 15/68 100.00 D, 10 - Year DFS CRC Lee,W. S. etal (2010) 3.47 (0.82, 14.71)22/25 19/28 19 90 Pages,F. etal (2005) 3.03 (1.94, 4.75) 110/160 74/176 40.12 Chen, Y.F. etal (2016) 1.06 (0.67, 1.67) 62/122 93/188 39.98 Subtotal (I-squared = 82.2%, p = 0.004) 2.04 (0.86, 4.84) 194/307 186/392 100.00 NOTE: Weights are from random effects analysis 2 .5 1

Figure 5. Stratified analyses describing ORs of the association between CD45RO⁺ T cell infiltration and DFS at 1-year, 3-year, 5-year and 10-year.

invasion (OR = 1.27, 95% CI 0.74 to 2.19, P = 0.385), or vascular invasion (OR = 1.19, 95% CI 0.92 to 1.54, P = 0.191) of patients (Fig. 6).

Sensitivity analysis. Sensitivity analyses were used to determine the influence of individual studies on the overall OR. As a result, the plot showed that all the individual studies had no important impact on the result for OS or DFS (data not shown).



Figure 6. Forest plots indicating ORs of the association between CD45RO⁺ T cell infiltration and clinicopathological features.

Publication bias. Funnel plot and Egger's test were performed to assess the publication bias of this meta-analysis. No significant publication bias existed between CD45RO⁺ T cell infiltration and OS or DFS in cancer patients (data not shown).

Discussion

As memory cells may prevent recurrence in cancer patients, CD45RO expression in TILs might predict immune response to recurrence after tumor resection. Although many studies have associated tumor-infiltrating CD45RO⁺ T cells and prognosis of solid tumors, their results were not consistent even controversial. In the present meta-analysis, we found that CD45RO⁺ T cell infiltration had a positive prognostic effect associated with survival in many types of solid tumors especially in CRC, HCC, GC and EC. In addition, increased density of CD45RO⁺ T cells was significantly inversely associated with TNM stage of solid tumor. We believe our study provides meaningful statistical evidence to report the important prognostic value of CD45RO⁺ T cell infiltration as a cancer fighter in patients with solid tumor for the first time.

However, the exact mechanisms underlying CD45RO⁺ T cell – mediated survival improvement still remain unclear. The possible explanations are as follows: it may partially relate to the features of CD45RO⁺ T cells, as they: (1) are the hallmark of adaptive immunity; (2) display a low-activation threshold; (3) vigorously proliferate despite minimal co-stimulation; and (4) persist over a life-time with stem cell-like multipotency and self-renewal characteristics³⁵. More importantly, tumor-infiltrating CD45RO⁺ T cells which experienced tumor antigens are probably effector memory CD8⁺ T cells (CD8⁺ Tem), can secret amount of INF- γ and granzyme to induce potent anti-tumor immune responses. *In situ* immune reactions can reflect and influence systematic anti-tumor capability. After the resection of primary tumor, central memory T cells (Tcm), as another subset of CD45RO⁺ memory T cells, increase and home to the secondary lymphatic organ and exhibit persistent anti-tumor effect via various mechanisms including INF- γ production. Thus, it is reasonable to speculate that the CD45RO⁺ T cells are able to respond to and eliminate residue tumor cells therefore improving survival.

Some limitations should be noted from this meta-analysis. First, significant heterogeneity observed across studies cannot be completely accounted despite the use of appropriate meta-analytic techniques with random-effect models. Second, there was only one study reporting the relevant data for OS in several cancers,

thus, we couldn't get a combined result for them. Finally, studies with negative results or small sample size may not be published, which can cause potential publication bias.

In conclusion, CD45RO⁺ memory T lymphocyte infiltration is associated with favorable clinical outcome of patients with solid tumor, implicating that these cells might be a potential biomarker for prognostic prediction for human solid malignances.

References

- 1. Motz, G. T. & Coukos, G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. *Nat Rev Immunol* 11, 702–711, doi:10.1038/nri3064 (2011).
- Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. *Cell* 144, 646–674, doi:10.1016/j.cell.2011.02.013 (2011).
 Leffers, N. *et al.* Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage
- ovarian cancer. *Cancer immunology, immunotherapy: CII* **58**, 449–459, doi:10.1007/s00262-008-0583-5 (2009). 4. Michie, C. A., McLean, A., Alcock, C. & Beverley, P. C. Lifespan of human lymphocyte subsets defined by CD45 isoforms. *Nature*
- analyses. European journal of epidemiology 25, 603-605, doi:10.1007/s10654-010-9491-z (2010).
 Higgins, J. P., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. *Bmj* 327, 557-560, doi:10.1136/bmj.327.7414.557 (2003).
- Kuritz, S. J., Landis, J. R. & Koch, G. G. A general overview of Mantel-Haenszel methods: applications and recent developments. *Annual review of public health* 9, 123–160, doi:10.1146/annurev.pu.09.050188.001011 (1988).
- DerSimonian, R. & Kacker, R. Random-effects model for meta-analysis of clinical trials: an update. *Contemporary clinical trials* 28, 105–114, doi:10.1016/j.cct.2006.04.004 (2007).
- 9. Egger, M., Davey Smith, G. & Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. *Bmj* **315**, 629–634 (1997).
- Yajima, R. et al. Tumor-infiltrating CD45RO(+) memory cells are associated with a favorable prognosis breast cancer. Breast cancer 23, 668–674, doi:10.1007/s12282-015-0622-y (2016).
- 11. Zhang, Z. et al. Infiltration of dendritic cells and T lymphocytes predicts favorable outcome in epithelial ovarian cancer. Cancer gene therapy 22, 198–206, doi:10.1038/cgt.2015.7 (2015).
- Paulsen, E. E. et al. CD45RO(+) Memory T Lymphocytes-a Candidate Marker for TNM-Immunoscore in Squamous Non-Small Cell Lung Cancer. Neoplasia 17, 839–848, doi:10.1016/j.neo.2015.11.004 (2015).
- Gao, Q. et al. Infiltrating memory/senescent T cell ratio predicts extrahepatic metastasis of hepatocellular carcinoma. Ann Surg Oncol 19, 455–466, doi:10.1245/s10434-011-1864-3 (2012).
- Hotta, K. et al. Prognostic significance of CD45RO+ memory T cells in renal cell carcinoma. British journal of cancer 105, 1191–1196, doi:10.1038/bjc.2011.368 (2011).
- Wakatsuki, K. *et al.* Clinical impact of tumor-infiltrating CD45RO(+) memory T cells on human gastric cancer. *Oncology reports* 29, 1756–1762, doi:10.3892/or.2013.2302 (2013).
- Lee, H. E. et al. Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. British journal of cancer 99, 1704–1711, doi:10.1038/sj.bjc.6604738 (2008).
- Li, Y. W. et al. Tumor-infiltrating macrophages can predict favorable prognosis in hepatocellular carcinoma after resection. Journal of cancer research and clinical oncology 135, 439–449, doi:10.1007/s00432-008-0469-0 (2009).
- Enomoto, K. et al. Prognostic importance of tumour-infiltrating memory T cells in oesophageal squamous cell carcinoma. Clin Exp Immunol 168, 186–191, doi:10.1111/j.1365-2249.2012.04565.x (2012).
- Chang, K. C., Huang, G. C., Jones, D. & Lin, Y. H. Distribution patterns of dendritic cells and T cells in diffuse large B-cell lymphomas correlate with prognoses. *Clin Cancer Res* 13, 6666–6672, doi:10.1158/1078-0432.CCR-07-0504 (2007).
- Anraku, M. et al. Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. The Journal of thoracic and cardiovascular surgery 135, 823–829, doi:10.1016/j.jtcvs.2007.10.026 (2008).
- Rauser, S. et al. High number of CD45RO+ tumor infiltrating lymphocytes is an independent prognostic factor in non-metastasized (stage I-IIA) esophageal adenocarcinoma. BMC Cancer 10, 608, doi:10.1186/1471-2407-10-608 (2010).
- Brunner, S. M. et al. Prognosis according to histochemical analysis of liver metastases removed at liver resection. The British journal of surgery 101, 1681–1691, doi:10.1002/bjs.9627 (2014).
- de Jong, R. A. *et al.* Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. *Gynecologic oncology* 114, 105–110, doi:10.1016/j.ygyno.2009.03.022 (2009).
- 24. Zhang, Y. et al. Prognostic significance of immune cells in the tumor microenvironment and peripheral blood of gallbladder carcinoma patients. Clinical & translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, doi:10.1007/s12094-016-1553-6 (2016).
- Lee, W. S., Park, S., Lee, W. Y., Yun, S. H. & Chun, H. K. Clinical impact of tumor-infiltrating lymphocytes for survival in stage II colon cancer. *Cancer* 116, 5188–5199, doi:10.1002/cncr.25293 (2010).
- Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960–1964, doi:10.1126/science.1129139 (2006).
- Peng, R. Q. et al. Co-expression of nuclear and cytoplasmic HMGB1 is inversely associated with infiltration of CD45RO+ T cells and prognosis in patients with stage IIIB colon cancer. BMC Cancer 10, 496, doi:10.1186/1471-2407-10-496 (2010).
- Wang, L., Zhai, Z. W., Ji, D. B., Li, Z. W. & Gu, J. Prognostic value of CD45RO(+) tumor-infiltrating lymphocytes for locally advanced rectal cancer following 30 Gy/10f neoadjuvant radiotherapy. *International journal of colorectal disease* 30, 753–760, doi:10.1007/s00384-015-2226-6 (2015).
- Pages, F. et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. The New England journal of medicine 353, 2654–2666, doi:10.1056/NEJMoa051424 (2005).
- Koelzer, V. H. et al. CD8/CD45RO T-cell infiltration in endoscopic biopsies of colorectal cancer predicts nodal metastasis and survival. Journal of translational medicine 12, 81, doi:10.1186/1479-5876-12-81 (2014).
- Kim, Y., Bae, J. M., Li, G., Cho, N. Y. & Kang, G. H. Image analyzer-based assessment of tumor-infiltrating T cell subsets and their prognostic values in colorectal carcinomas. *PLoS One* 10, e0122183, doi:10.1371/journal.pone.0122183 (2015).
- Lee, W. S., Kang, M., Baek, J. H., Lee, J. I. & Ha, S. Y. Clinical impact of tumor-infiltrating lymphocytes for survival in curatively resected stage IV colon cancer with isolated liver or lung metastasis. *Ann Surg Oncol* 20, 697–702, doi:10.1245/s10434-012-2752-1 (2013).
- Nosho, K. et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 222, 350–366, doi:10.1002/path.2774 (2010).
- Chen, Y. et al. A Novel Immune Marker Model Predicts Oncological Outcomes of Patients with Colorectal Cancer. Ann Surg Oncol 23, 826–832, doi:10.1245/s10434-015-4889-1 (2016).
- Woodland, D. L. & Kohlmeier, J. E. Migration, maintenance and recall of memory T cells in peripheral tissues. Nat Rev Immunol 9, 153–161, doi:10.1038/nri2496 (2009).

Acknowledgements

We thank all the members of the departments who helped in this study.

Author Contributions

G.M.H. conceived of the study, participated in its design, extracted data, performed the statistical analysis and drafted the manuscript. S.M.W. participated in its design and performed the statistical analysis. Two authors read and approved the final manuscript.

Additional Information

Supplementary information accompanies this paper at doi:10.1038/s41598-017-11122-2

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017